Evodiamine attenuates chemotherapy-induced peripheral neuropathy by mediating macrophage M2 polarization and inhibiting the upregulation of the p38 MAPK-TRPV1 axis in rat dorsal root ganglia
Evodiamine alleviates CIPN through a novel neuroimmune mechanism involving M2 macrophage polarization and inhibition of the p38/MAPK-TRPV1 axis in DRG neurons. These findings establish macrophage polarization as a key therapeutic target and highlight evodiamine's potential as a natural therapeutic agent for CIPN management.
Authors
- Pei pei WU (ORCID: https://orcid.org/0009-0007-3827-2457)
- Rong Yang (ORCID: https://orcid.org/0000-0002-6112-3149)
- Kequn Xu (ORCID: https://orcid.org/0000-0003-3782-0152)
- Qiangqiang Zhou
- Zaiwang Li (ORCID: https://orcid.org/0000-0003-3738-3917)
- Yong Chen (ORCID: https://orcid.org/0000-0003-1612-8351)
- Qiang Jiang (ORCID: https://orcid.org/0000-0002-9880-9435)
Institutions
- Changzhou No.2 People's Hospital (CN)
Publication Details
- Journal
- Molecular Pain
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1177/17448069251392037
- Primary Topic
- Quinazolinone synthesis and applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00